Table5_Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.docx

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF.MethodsRandomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA.ResultsA total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM.ConclusionCompared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results.Systematic Review Registrationidentifier, CRD42022303938.</p

Table1_Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.docx

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF.MethodsRandomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA.ResultsA total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM.ConclusionCompared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results.Systematic Review Registrationidentifier, CRD42022303938.</p

Table4_Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.docx

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF.MethodsRandomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA.ResultsA total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM.ConclusionCompared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results.Systematic Review Registrationidentifier, CRD42022303938.</p

Table3_Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.docx

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF.MethodsRandomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA.ResultsA total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM.ConclusionCompared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results.Systematic Review Registrationidentifier, CRD42022303938.</p

Table2_Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.docx

BackgroundHeart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF.MethodsRandomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA.ResultsA total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM.ConclusionCompared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results.Systematic Review Registrationidentifier, CRD42022303938.</p

Polarization-Enhanced Photovoltaic Effects in a High-Temperature Molecular Ferroelectric [C₆N₂H₁₈][SbI₅]‑Based Solar Device

Molecular ferroelectrics with narrow bandgaps has great potential in the photoelectric field, but the outstanding species are still scarce. Herein, [C6N2H18]­[SbI5] has been demonstrated as a room-temperature (RT) molecular ferroelectric and applied to the organic–inorganic hybrid solar cells as the light-absorbing layer. The polar orthorhombic structure was solved by single-crystal XRD. The inherent RT ferroelectricity was revealed by hysteresis measurements with superior saturation polarization (Ps), remanent polarization (Pr), and coercive field (Ec) as 12.55 μC/cm2, 10.78 μC/cm2, and 0.33 kV/cm, respectively. The [C6N2H18]­[SbI5]-based solar device exhibits a significant photovoltaic (PV) effect under AM 1.5 G illumination with Voc ∼ 0.43 V, Jsc ∼ 35.17 μA/cm2, and a fast response time of ∼0.33 ms. A dramatical enhancement in PV performance has been achieved by turning the ferroelectric polarization, leading to the maximum Voc ∼ 0.75 V, Jsc ∼ 1.09 mA/cm2, and a power conversion efficiency (PCE) of 0.29%. This work offers a bright avenue for molecular ferroelectrics in optoelectronic devices

Polarization-Enhanced Photovoltaic Effects in a High-Temperature Molecular Ferroelectric [C₆N₂H₁₈][SbI₅]‑Based Solar Device

Molecular ferroelectrics with narrow bandgaps has great potential in the photoelectric field, but the outstanding species are still scarce. Herein, [C6N2H18]­[SbI5] has been demonstrated as a room-temperature (RT) molecular ferroelectric and applied to the organic–inorganic hybrid solar cells as the light-absorbing layer. The polar orthorhombic structure was solved by single-crystal XRD. The inherent RT ferroelectricity was revealed by hysteresis measurements with superior saturation polarization (Ps), remanent polarization (Pr), and coercive field (Ec) as 12.55 μC/cm2, 10.78 μC/cm2, and 0.33 kV/cm, respectively. The [C6N2H18]­[SbI5]-based solar device exhibits a significant photovoltaic (PV) effect under AM 1.5 G illumination with Voc ∼ 0.43 V, Jsc ∼ 35.17 μA/cm2, and a fast response time of ∼0.33 ms. A dramatical enhancement in PV performance has been achieved by turning the ferroelectric polarization, leading to the maximum Voc ∼ 0.75 V, Jsc ∼ 1.09 mA/cm2, and a power conversion efficiency (PCE) of 0.29%. This work offers a bright avenue for molecular ferroelectrics in optoelectronic devices

Polarization-Enhanced Photovoltaic Effects in a High-Temperature Molecular Ferroelectric [C₆N₂H₁₈][SbI₅]‑Based Solar Device

Molecular ferroelectrics with narrow bandgaps has great potential in the photoelectric field, but the outstanding species are still scarce. Herein, [C6N2H18]­[SbI5] has been demonstrated as a room-temperature (RT) molecular ferroelectric and applied to the organic–inorganic hybrid solar cells as the light-absorbing layer. The polar orthorhombic structure was solved by single-crystal XRD. The inherent RT ferroelectricity was revealed by hysteresis measurements with superior saturation polarization (Ps), remanent polarization (Pr), and coercive field (Ec) as 12.55 μC/cm2, 10.78 μC/cm2, and 0.33 kV/cm, respectively. The [C6N2H18]­[SbI5]-based solar device exhibits a significant photovoltaic (PV) effect under AM 1.5 G illumination with Voc ∼ 0.43 V, Jsc ∼ 35.17 μA/cm2, and a fast response time of ∼0.33 ms. A dramatical enhancement in PV performance has been achieved by turning the ferroelectric polarization, leading to the maximum Voc ∼ 0.75 V, Jsc ∼ 1.09 mA/cm2, and a power conversion efficiency (PCE) of 0.29%. This work offers a bright avenue for molecular ferroelectrics in optoelectronic devices

Direct Observation of Solvent Donor Number Effect on Lithium–Oxygen Battery Capacity via a Nanoarray Cathode Model

The solvent properties are critical factors that strongly influence the capacities and cycle lives of lithium–oxygen (Li–O2) batteries. In previous studies of solvent effects, disk electrodes are prototypes far from practical application while practical composite electrodes are interfered by additives. Herein, we propose MnO2 nanoarrays as a cathode model to directly observe the effect of the tunable donicity of dimethyl sulfoxide (DMSO)–tetra (ethylene glycol) dimethyl ether (G4) binary solvent. The facilely prepared MnO2 nanoarrays on carbon clothes not only mimic carbon-supported catalysts but also provide an open architecture that helps distinguish discharge products from complex electrodes without further characterizations. Using nanoarray models, this work directly observes the morphologies of discharge products that gradually evolve from conformal films to toroid-like particles with the increase in the DMSO ratio in the binary solvents. Thus, the Li–O2 battery capacities are proportional to the donicities of the binary solvents. However, the reactive solvent that provides high donicity greatly deteriorates the cycle performance. A compromise should be achieved between capacity and stability when tuning the donicity of the binary solvent. The novel nanoarray model and fundamental findings in this work will further help the electrolyte optimization for Li–O2 batteries

MOESM1 of Temporary CXCR3 and CCR5 Antagonism Following Vaccination Enhances Memory CD8 T Cell Immune Responses

Temporary CXCR3 and CCR5 Antagonism Following Vaccination Enhances Memory CD8 T Cell Immune Response